Key result
A high-risk SAMe-TT2R2 score (≥2) was associated with a lower median time in therapeutic range compared to a low-risk score, but not with adverse events.
Why the study?
Does the SAMe-TT2R2 score predict time in therapeutic range and adverse events in patients with nonvalvular atrial fibrillation on vitamin K antagonists?
Cohort (n=263)
No
Does the SAMe-TT2R2 score predict time in therapeutic range and adverse events in patients with nonvalvular atrial fibrillation on vitamin K antagonists?
The SAMe-TT2R2 score is a useful tool to predict which patients with nonvalvular AF on VKAs will achieve adequate time in therapeutic range, though it may not predict adverse events.
Answers are grounded in this paper and cite their sources.
High-risk SAMe-TT2R2 flags lower TTR; hypothesis-generating and should not yet guide anticoagulation decisions.
Background: The SAMe-TT2R2 score was developed to predict which patients on oral anticoagulation with vitamin K antagonists (VKAs) will reach an adequate time in therapeutic range (TTR) (> 65%-70%). Studies have reported a relationship between this score and the occurrence of adverse events. Objective: To describe the TTR according to the score, in addition to relating the score obtained with the occurrence of adverse events in patients with nonvalvular atrial fibrillation (AF) on oral anticoagulation with VKAs. Methods: Retrospective cohort study including patients with nonvalvular AF attending an outpatient anticoagulation clinic of a tertiary hospital. Visits to the outpatient clinic and emergency, as well as hospital admissions to the institution, during 2014 were evaluated. The TTR was calculated through the Rosendaal´s method. Results: We analyzed 263 patients (median TTR, 62.5%). The low-risk group (score 0-1) had a better median TTR as compared with the high-risk group (score ≥ 2): 69.2% vs. 56.3%, p = 0.002. Similarly, the percentage of patients with TTR ≥ 60%, 65% or 70% was higher in the low-risk group (p < 0.001, p = 0.001 and p = 0.003, respectively). The high-risk group had a higher percentage of adverse events (11.2% vs. 7.2%), although not significant (p = 0.369). Conclusions: The SAMe-TT2R2 score proved to be effective to predict patients with a better TTR, but was not associated with adverse events. Fundamento: O escore SAMe-TT2R2 foi desenvolvido visando predizer quais pacientes em anticoagulação oral com antagonistas da vitamina K (AVKs) atingirão um tempo na faixa terapêutica (TFT) adequado (> 65%-70%) no seguimento. Estudos também o relacionaram com a ocorrência de eventos adversos. Objetivos: Descrever o TFT de acordo com o escore, além de relacionar a pontuação obtida com a ocorrência de eventos adversos adversos em pacientes com fibrilação atrial (FA) não valvar em anticoagulação oral com AVKs. Métodos: Estudo de coorte retrospectivo incluindo pacientes com FA não valvar em acompanhamento em ambulatório de anticoagulação de um hospital terciário. Foi realizada uma avaliação retrospectiva de consultas ambulatoriais, visitas a emergência e internações hospitalares na instituição no período de janeiro-dezembro/2014. O TFT foi calculado aplicando-se o método de Rosendaal. Resultados: Foram analisados 263 pacientes com TFT mediano de 62,5%. O grupo de baixo risco (0-1 ponto) obteve um TFT mediano maior em comparação com o grupo de alto risco (≥ 2 pontos): 69,2% vs. 56,3%, p = 0,002. Da mesma forma, o percentual de pacientes com TFT ≥ 60%, 65% ou 70% foi superior nos pacientes de baixo risco (p < 0,001, p = 0,001 e p = 0,003, respectivamente). Os pacientes de alto risco tiveram um percentual maior de eventos adversos (11,2% vs. 7,2%), embora não significativo (p = 0,369). Conclusões: O escore SAMe-TT2R2 foi uma ferramenta eficaz na predição do TFT em pacientes com FA em uso de AVKs para anticoagulação, porém não se associou à ocorrência de eventos adversos.
No takes yet. Share an insight, caveat, or question.
Júnior et al. (2017) conducted a cohort in Nonvalvular atrial fibrillation (n=263). High-risk SAMe-TT2R2 score (≥ 2) vs. Low-risk SAMe-TT2R2 score (0-1) was evaluated on Median time in therapeutic range (TTR) (p=0.002). A high-risk SAMe-TT2R2 score (≥2) was associated with a lower median time in therapeutic range compared to a low-risk score, but not with adverse events.
Synapse has enriched 10 related papers. Consider them for comparative context: